Compare Citius Pharmaceuticals Inc (CTXR) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Jumia Technologies AG - ADR — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while Jumia Technologies AG - ADR trades at $6.3 (market cap $719.58M). The key difference: Jumia Technologies AG - ADR is far larger — about 36× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| CTXR | JMIA | |
|---|---|---|
Market Cap | $20.01M | $719.58M |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $14.60 |
52-Week Low | $0.48 | $5.69 |
Enterprise Value | $16.23M | $666.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
JMIA trades at $6.245, up 4.08% on the day, amid a bearish technical signal and mixed fundamentals. The company reported revenue of $188.93M for 2025 with a gross profit margin of 54.75%, but net losses persist, and recent earnings have missed expectations. Analyst consensus is strongly bullish with 71.43% buy ratings, while technical indicators show selling pressure.
The outlook hinges on JMIA's path to profitability, targeting Q4 2026 breakeven and 2027 profitability. Risks include high cash burn and competitive pressures, but gross profit growth and strategic partnerships offer potential upside for patient investors focused on the African e-commerce market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
